You are here

NOVEL ANTIMIGRANE AGENT – ZOLMITRIPTAN: A REVIEW

Journal Name:

Publication Year:

Abstract (2. Language): 
Present survey is conducted on two species of Cuscuta (C. chinensis and C. reflexa) which are distributed in different parts of Nadia district especially in Kalyani Township. 30 angiospermic host plants have been identified out of which 25 angispermic plants are infected by C. reflexa and only 5 plants has been attacked by C. chinensis. All angiospermic plants are distributed in 28 genera and 20 families. 2 plants has been identified as pseudo parasite and 2 plants belonging to pteridophytic group are also attacked by Cuscuta. Detailed structure and development of haustoria have been studied on 8 angiospermic plants. Mikania cordata is identified as primary host plant of Cuscuta. Structure of haustorium is variable which is dependent on some factors. Migraine is a chronic neurological disorder characterized by recurrent moderate to severe headaches often in association with a number of autonomic nervous system symptoms. Typically the headache is unilateral (affecting one half of the head) and pulsating in nature, lasting from 2 to 72 hours. Associated symptoms may include nausea, vomiting, photophobia, phonophobia (increased sensitivity to sound) and the pain is generally aggravated by physical activity. Zolmitriptan is a selective serotonin receptor agonist of the 1B and 1D subtype. It is a triptan, used in the acute treatment of migraine attacks with or without aura and cluster headaches. The efficacy of zolmitriptan appears to be maintained, with no tachyphylaxis, following repeated administration for multiple attacks of migraine over a prolonged period of time, with high headache response rates reported over all attacks.
22
38

REFERENCES

References: 

1. Rang H.P, Dale M.M, Ritter J.M, Flower
R.J. “Pharmacology”. Sixth Edition, Churchill
Livingstone Elsevier, USA, 2007.
2. Tripathi K.D. “Essentials of Medical
Pharmacology”. Sixth Edition, Jaypee
Brothers Medical Publishers Pvt Ltd, New
Delhi, 2010.
3. Peter J. Goads by, Rager Yates.,
Zolmitriptan intranasal: A review of the
pharamcokinetics and clinical efficacy,
Headache. 46 (2006) 138-149.
4. M.D. Ferrari, K.I. Roon, R.B.Lipton, et al.,
Oral triptans (Serotonin 5-HT (1B/1D)
agonists) in acute migraine treatment: A
meta-analysis of 53 trials. Lancet 358 (2001)
1668.
5. IP ADDENDUM 2012. Page No: 2971
6. Zolmitriptan – Wikipedia
(http://en.wikipedia.org/wiki/Zolmitriptan).
7. Zolmitriptan – Online library
(http://onlinelibrary.wiley.com/doi/10.1038
/sj.bjp.0704979/full).
8. Zolmitriptan – Faqs
(http://www.faqs.org/patents/app/201001
45064)
9. Zolmitriptan – Drugs
(http://www.drugs.com/ppa/zolmitriptan.h
tml)
10. Zolmitriptan – Drug Bank
(http://www.drugbank.ca/drugs/DB00315)
11. Danavena R , Bhoomaiah B, Phani.
R.S.CH, K Balamuralikrishna. Validated RP –
HPLC method for the estimation of
zolmitriptan in formulation.
Pharmacophore.2011; 2(2):150-5.
12. Soloman GD, Cady RK, Klapper JA, Earl
NL, Saper JR, Ramadan NM. Clinical efficacy
and tolerability of 2.5 mg zolmitriptan for
Review Article CODEN: IJPRNK ISSN: 2277-8713
Bonthu Satyanarayana, IJPRBS, 2013; Volume 2(5):22-38 IJPRBS
Available Online at www.ijprbs.com
38
the acute treatment of migraine.
Neurology. 1997 Nov; 49(5):1219-56.
13. Zolmitriptan – Mims
(http://www.mims.com/India/drug/info/zol
mitriptan)
14. Zolmitriptan – Nlm
(http://www.nlm.nih.gov/medlineplus/drug
info/meds/a601129.html)
15. Zolmitriptan – Medscape
(http://www.medscape.com/viewarticle/50
3118)
16. Martindale, The Complete Drug
Reference, 35th ed. London: Pharmaceutical
Press; 2006.
17. Rapoport AM, Ramadan AM, Adelman
JU et al. Optimizing the dose of zolmitriptan
for the acute treatment of migraine.
Neurology.1997 Nov;49(5):1210-8.

Thank you for copying data from http://www.arastirmax.com